Active	Status	Sponsor type	Region	Phase	Filter
4 Active 10 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Conlon, Kevin C
NCT05660083: Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)	Recruiting	2	36	US	L-NMMA, iNOS inhibitor	The Methodist Hospital Research Institute, Novartis Pharmaceuticals	HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer	12/26	12/28
QUILT-3.017, NCT03476681: Study of NEO-201 in Solid Tumors Expansion Cohorts	Recruiting	1/2	121	US	NEO-201 in combination with pembrolizumab, IHC screening for NEO-201 target	Precision Biologics, Inc	Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer	01/28	01/29
NCT00001582: Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer	Completed	N/A	902	US		National Cancer Institute (NCI)	T-cell Lymphoma, B-Cell Lymphoma, ATL, Myeloma	03/23	03/23
NCT03189108: Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors	Completed	N/A	22	US		National Cancer Institute (NCI)	Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Cancer	05/23	05/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Conlon, Kevin C
NCT05660083: Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)	Recruiting	2	36	US	L-NMMA, iNOS inhibitor	The Methodist Hospital Research Institute, Novartis Pharmaceuticals	HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma, TNBC - Triple-Negative Breast Cancer	12/26	12/28
QUILT-3.017, NCT03476681: Study of NEO-201 in Solid Tumors Expansion Cohorts	Recruiting	1/2	121	US	NEO-201 in combination with pembrolizumab, IHC screening for NEO-201 target	Precision Biologics, Inc	Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer	01/28	01/29
NCT00001582: Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer	Completed	N/A	902	US		National Cancer Institute (NCI)	T-cell Lymphoma, B-Cell Lymphoma, ATL, Myeloma	03/23	03/23
NCT03189108: Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors	Completed	N/A	22	US		National Cancer Institute (NCI)	Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Cancer	05/23	05/23